(Q39365133)

11 September 2017

title

Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine (English)

1 reference

11 September 2017

1 reference

Dahlof C

1

1 reference

11 September 2017

Lines C

series ordinal

2

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

Expert Opinion on Investigational Drugs

11 September 2017

published in

1 reference

11 September 2017

volume

8

1 reference

11 September 2017

issue

5

1 reference

11 September 2017

page(s)

671-685

1 reference

Migraine symptoms: results of a survey of self-reported migraineurs

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Ergotamine dependency--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Sumatriptan in clinical practice: a 2-year review of 453 migraine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Rizatriptan has central antinociceptive effects against durally evoked responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Coronary side-effect potential of current and prospective antimigraine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Sumatriptan and cerebral perfusion in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

The effect of ergotamine and dihydroergotamine on cerebral blood flow in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Sumatriptan clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Serotonin 5-HT1B/1D Receptor Agonists in Migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.671

21 January 2018

Identifiers

DOI

10.1517/13543784.8.5.671

1 reference

11 September 2017

1 reference